What we do Lyka Labs Limited develops, manufactures, and markets pharmaceutical formulations, bulk drugs, and health products, including human and veterinary medicines and medical devices. |
Founded in 1,983 |
Market share Recognized export house with a reputable presence in domestic pharmaceutical and export markets, expanding into regulated markets like Europe and UK. |
Problem solved Provides effective pharmaceutical solutions for infections, cancer, cardiovascular, skin disorders, and specialized therapeutic areas. |
Top clients or who we serve Serves healthcare sectors including hospitals, clinics, veterinary markets; primarily B2B with growing B2C engagements via domestic marketing. |
Key management Mr. Kunal Gandhi, Managing Director & CEO; Mr. Yogesh B Shah, Whole-time Director & CFO; Mrs. Archana S Yadav, Independent Director. |
Our journey and innovations Started with formulations and bulk drugs, expanded into diagnostics, launched India's first Glutathione Injection, and advanced into gynecology and ART. |
Where we operate India (Domestic), Export markets across various countries; aiming to enter Europe and UK markets soon. |
Top products or what we offer Antibiotics, topical steroids, anti-cancer, cardiovascular, anti-inflammatory drugs, lyophilized injections, topical preparations, and ART solutions. |
Top brands FertiNova division for gynecology and ART; Life-saving antibiotics; Glutathione injection - first in India. |
Raw materials needed Active pharmaceutical ingredients (APIs), chemicals for formulations and lyophilisation processes. |
Raw materials supplier Not specified publicly. |
Recurring vs cyclical contribution Revenue comprises recurring pharmaceutical sales with some cyclical export contracts driven by government tenders. |
Our industry position Strong GMP/GLP compliance with growing domestic and export markets; recognized for export performance. |
Financial highlights FY 2025 consolidated revenue: Rs. 140.7 Cr; net profit: Rs. 8.1 Cr; turnaround from previous year losses. |
Geographical revenue split Domestic: 85 Cr (60%); Exports: 49 Cr (40%). |
Order book - |
Whats driving growth Expansion in human and veterinary brands, new product launches, capacity upgrade, entry into regulated markets, and ART segment. |
Our future plans Enhance lyophilisation capacity by 50% by FY 2026; deepen domestic market; grow gynecology and ART division. |
Our green promise - |
Our people and values Focus on integrity, compliance, and high standards; structured governance; emphasis on diversity with independent directors. |
Key challenges ahead Foreign exchange volatility, export market uncertainties, regulatory compliance for global expansion. |
Interesting facts First company in India to launch Glutathione Injection; ventured into Assisted Reproductive Technology with FertiNova. |
Risks and strategy Mitigates export risks through domestic expansion; invests in R&D and capacity upgrades to sustain growth and compliance. |
